0001285550-25-000012
SEC filingClearPoint Neuro raised $28.7M in debt and $3.3M in equity in Q2 2025, boosting cash to $41.5M, with no segment-level profitability disclosed.
As of June 30, 2025, ClearPoint Neuro held $41.5M in cash and cash equivalents, a significant increase from $20.1M at December 31, 2024, driven by debt and equity raises. Total assets were $62.9M, including $6.3M in net inventory and $4.3M in net accounts receivable. Stockholders' equity stood at $19.7M, down from $25.4M at year-end due to cumulative losses. The company has a cumulative deficit of $203.2M. Management states existing cash is sufficient for at least the next twelve months.
The company has operating lease liabilities totaling $6.6M (current $0.3M, non-current $6.3M) for office and manufacturing space. Notable new lease: a 132-month lease in San Diego commenced June 2025, adding a right-of-use asset of $3.3M. The company settled a legal matter in August 2025 with no material impact. No other purchase commitments or off-balance-sheet obligations were disclosed.
ClearPoint Neuro does not pay dividends or repurchase shares. In May 2025, it issued $30.0M principal of notes (net $28.7M after discount and costs) due in 2031, bearing interest at SOFR + 3.95% (min 8.25%, max 9.50%), with 50% PIK interest for first six quarters. Contemporaneously, it raised $3.3M through a registered direct offering of 275,808 shares at $12.69. Capital expenditures were $0.3M for six months, or 1.5% of revenue, primarily for property and equipment.
The company operates as a single reportable segment. The Chief Operating Decision Maker (CEO) reviews disaggregated revenue by product line but uses consolidated net income to assess performance and allocate resources. Revenue is derived predominantly in the United States. The revenue footnote breaks down three lines: Biologics & drug delivery ($9.4M), Neurosurgery navigation & therapy ($6.7M), and Capital equipment & software ($1.6M) for the six months ended June 30, 2025. All revenue is recognized at a point in time or over time depending on the nature of the performance obligation.
Net loss for H1 FY2025 was $11.9 million, while operating cash flow was -$8.7 million. The difference is largely due to non-cash charges: share-based compensation ($4.2M), depreciation/amortization ($0.5M), and payment-in-kind interest ($0.2M). Working capital changes provided a net use of cash: accounts receivable decreased $0.2M, inventory decreased $0.5M, but accounts payable and accrued expenses decreased $1.9M, and contract liabilities decreased $0.6M. The company's capex was minimal at $0.3 million. Financing activities were strong, with $28.7 million in net proceeds from note payable and $3.3 million from stock offerings. Overall, the company's cash position improved by $21.6 million, ending at $41.7 million. The negative free cash flow (CFO minus capex) of -$9.0 million was fully funded by financing. The company's ability to generate positive CFO remains dependent on achieving profitability.